再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

国庆日休市 09-30 16:08:27

20.640

+0.260

+1.28%

最高21.000	最低20.260	成交量554.40万
今开20.480	昨收20.380	日振幅3.63%
总市值234.88亿	流通市值234.88亿	总股本11.38亿
成交额1.15亿	换手率0.49%	流通股本11.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":20.64,"timestamp":1790755707010,"preClose":20.38,"halted":0,"volume":5544000,"delay":0,"changeRate":0.012757605495583984,"floatShares":1138000000,"shares":1138000000,"eps":-0.160262,"marketStatus":"国庆日休市","change":0.26,"latestTime":"09-30 16:08:27","open":20.48,"high":21,"low":20.26,"amount":114544472,"amplitude":0.03631,"askPrice":20.64,"askSize":2000,"bidPrice":20.62,"bidSize":30600,"shortable":3,"etf":0,"ttmEps":-1.331863,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":20.38,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.079666284991696,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU0348767384.USD","BK1161","BK1588","LU2778985437.USD","LU2328871848.SGD","01276","06955","IE00B543WZ88.USD","LU0348735423.USD","LU2476274308.USD","BK1574","LU1961090484.USD","LU0359201885.HKD","09995","02162","IE00BPRC5H50.USD","BK1583","LU0359202008.SGD","LU0196878994.USD","06978","02157","IBBQ","LU1720050803.USD","LU0417516571.SGD","LNGR","159992","LU0634319403.HKD","06990","LU2476274720.SGD","LU0348827113.USD","09688","LU0561508036.HKD","BK1587","BK1191","09926","LU1023057109.AUD","LU0348825331.USD","LU0359201612.USD","LU1794554557.SGD","LU0348783233.USD","LU1969619763.USD","LU2488822045.USD","LU2543165471.USD","LU0417516738.SGD","LU0348784397.USD","KURE","IE00B5MMRT66.SGD","LU0417516902.SGD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103832332","title":"再鼎医药：The Goldman Sachs Group, Inc.同日披露权益变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1103832332","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103832332?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:42","pubTimestamp":1790329352,"startTime":"0","endTime":"0","summary":"The Goldman Sachs Group, Inc.于2026年9月22日好仓持股增加，由5550.23万股增至6247.61万股。同日，淡仓持股由4288.86万股增至4888.86万股，原因是根据证券借贷协议借入股份。The Goldman Sachs Group, Inc.此次增持前持有再鼎医药好仓5550.23万股，占比4.88%；增持后持股量为6247.61万股，好仓比例升至5.49%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014674.SGD","LU0828237510.HKD","LU1242518931.SGD","03347","02696","LU0140636845.USD","LU1880383366.USD","LU0856984785.SGD","688428","LU2328871848.SGD","BK1583","LU0516422366.SGD","BK1141","LU0348766576.USD","06990","09926","LU1303224171.USD","KURE","LU0516423174.USD","02162","09688","LU3063872942.SGD","BK1515","02268","BK4581","LU0456846285.SGD","LU1719994722.HKD","06160","01548","LU2399975544.HKD","XBI","399441","LU0561508036.HKD","LU1770034418.SGD","SG9999002463.SGD","LU1242518857.USD","161726","LU2039709279.SGD","LU1961090484.USD","LU0540923850.HKD","SG9999002562.SGD","LU0348825331.USD","01877","09995","BK1576","09969","HK0000306701.USD","LU0348783233.USD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","06160","01877","01801","LU0029874061.USD","LU0348735423.USD","LU0516423091.SGD","LU2097828805.USD","IBBQ","02142","LU0417516902.SGD","LU1719994722.HKD","LNGR","LU1993786604.SGD","LU0348784397.USD","LU1152091754.HKD","09995","09926","LU0359202008.SGD","MEDX","LU1251922891.USD","06978","LU2039709279.SGD","LU1770034418.SGD","LU0828237510.HKD","LU0128526141.USD","KCE","LU1226287792.SGD","01093","06185","LU2476274720.SGD","02269","01177","LU0315179316.USD","BK1515","LU0039217434.USD","HK0000165453.HKD","KURE","LU0708995583.HKD","09688","LU0314109678.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","SG9999002562.SGD","LU3063872942.SGD","02616","LU1226288253.USD","600109","LU1152091168.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129657625","title":"再鼎医药：摩根大通减持，好仓比例降至10.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129657625","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129657625?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:43","pubTimestamp":1790156603,"startTime":"0","endTime":"0","summary":"摩根大通于2026年9月18日以每股均价20.5723港元场外卖出602.21万股再鼎医药（09688）股份，涉资约1.24亿港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次减持前持有再鼎医药好仓1.28亿股，占比11.23%；减持后持股量为1.22亿股，好仓比例降至10.7%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152865683","title":"再鼎医药：The Goldman Sachs Group, Inc.减持，好仓比例降至4.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152865683","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152865683?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:24","pubTimestamp":1790155454,"startTime":"0","endTime":"0","summary":"于2026年9月18日，The Goldman Sachs Group, Inc.因结束场外衍生品合约（OTC derivatives contracts）而减持再鼎医药股份，好仓减少。该笔交易属场外衍生品交易，并非在二级市场直接买卖正股。The Goldman Sachs Group, Inc.此次减持前持有再鼎医药好仓5765.08万股，占比5.07%；减持后持股量为5657.30万股，好仓比例降至4.97%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06606","03347","02269","09995","06618","06978","09966","09606","03759","06622","01801","02137","09688","02359","01672","02268","06996","00241"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2668353929","title":"纳斯达克中国金龙指数涨超0.5%，金山云涨4.58%，再鼎医药涨5.00%，哔哩哔哩涨3.33%，阿里巴巴涨3.01%，","url":"https://stock-news.laohu8.com/highlight/detail?id=2668353929","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668353929?lang=zh_cn&edition=full","pubTime":"2026-09-18 21:31","pubTimestamp":1789738276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4614","BABX","ALBmain","LU1046422090.SGD","BABW","BK4581","LU1008478684.HKD","LU2148611432.USD","LU0661504455.SGD","BK4531","LU0072913022.USD","BK4577","LU0821914370.USD","LU1003077747.HKD","LU2488822045.USD","BABU","BK4588","IE00BF5LJ272.USD","09688","BK4533","LU1242518931.SGD","BK4565","LU1152091168.USD","BK4579","LU1105468828.SGD","BK4558","BK4554","BK4527","BABA","BK4513","LU1048596156.SGD","LU0348814723.USD","ONLN","BK4608","LU0251143458.SGD","BK4085","LU0348816934.USD","BK4548","BK4510","LU0067412154.USD","BK4543","BK4116","LU0918141705.HKD","09988","ECX","LU1051768304.USD","LU0328353924.USD","BK4526","LU0880133367.SGD","LU0545039389.USD","BK4535","LU0738911758.USD","DRAG","LU1880383366.USD","LU2226246903.HKD","HXC","LU0456842615.SGD","LU0651947912.USD","LU1048588211.SGD","CLIX","BK4505","LU0501845795.SGD","BABC","IE00BFMHRM44.USD","LU1688375341.USD","KBAB","BK4124","LU0651946864.USD","LU1267930227.SGD","LU0128525689.USD","BK4122","LU0310800965.SGD","LU1235294995.USD","BK4509","KC","BK4534","LU0949170772.SGD","LU1769817096.USD","BK4503","LU0979878070.USD","BBYY","LU1515016050.SGD","ZLAB","09626","BK4607","LU1242518857.USD","LU1282648689.USD","LU1769817179.HKD","BK4585","LU1823568750.SGD","BK4575","IE00B0JY6N72.USD","BILI","03896","BK4566","LU0072462343.USD","BK4524","LU1152091754.HKD","LU1051769294.HKD","LU0052756011.USD","BK4538","BK4220","LU0106959298.USD","BK4502","BK4077","BK4587","LU0047713382.USD","BK4563","BK4504","LU1046421795.USD","BK4139","BABO","LU0797268264.HKD","LU0553294199.USD","LU0918141887.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919445","title":"港股异动 | 生物医药股悉数走高 十部门印发医药十五五规划 机构看好医药迎“Claude”时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919445","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919445?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:04","pubTimestamp":1789697085,"startTime":"0","endTime":"0","summary":"消息面上，工信部等十部门联合发布《医药工业发展\"十五五\"规划》，提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。浙商证券表示，高频迭代短期将会带来验证阶段需求的井喷，但长期来看，高速迭代可能会带来平台能力的提升和泛化，能够持续迭代的发现平台能力提升或是行业的核心，医药行业的Claude也许将要到来。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","09939","BK4585","KCAI","02142","BK1515","BK1588","VXUS","BK1141","BK1583","399441","06127","161726","BK4581","01672","XBI","07666","BK4588","BK1576","LU2488822045.USD","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668813919","title":"生物医药概念走强 再鼎医药（09688）涨超4% 十部门出台医药工业十五五规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2668813919","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668813919?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:45","pubTimestamp":1789695942,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药概念走强，截至发稿，金斯瑞生物科技 涨4.78%，再鼎医药涨4.57%，君实生物涨3.32%，泰格医药涨1.93%，药明生物涨1.70%。消息面上，工业和信息化部、国家发展改革委等十部门联合发布《医药工业发展“十五五”规划》。《规划》提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991931","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","BK4531","01877","LU0417516902.SGD","KURE","03347","BK1521","LU1688375341.USD","LU0417516738.SGD","LU0348827113.USD","LU0456846285.SGD","LU0128522744.USD","SG9999002463.SGD","LU0561508036.HKD","LU0572944931.SGD","BK1583","LU0043850808.USD","LU0128526141.USD","LU0588546209.SGD","01548","399441","LU0181495838.USD","BK1161","BK1610","LU0516423174.USD","XBI","BK1141","LU3063872942.SGD","HK0000320264.USD","BK4139","09688","LU0320764599.SGD","LU0348825331.USD","LU0326950275.SGD","161726","LU0320764243.SGD","LU0516423091.SGD","LU0140636845.USD","ZLAB","BK4588","LU0516422366.SGD","LU2488822045.USD","LU0979878070.USD","LU0634319403.HKD","LU0856984785.SGD","02269","LU1242518931.SGD","LU0348735423.USD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617679?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","02637","01177","01477","LU0140636845.USD","BK0060","BK0239","LU2488822045.USD","LU0417516902.SGD","IE00B0JY6N72.USD","LU2148510915.USD","LU0456846285.SGD","600276","LU2097828557.USD","MEDX","LNGR","IE00BZ08YS42.EUR","LU1820825898.SGD","BK1515","LU1328615791.USD","159992","BK0183","LU0348825331.USD","06978","LU1655091616.SGD","LU2580892789.USD","LU0516423174.USD","09688","LU1255011170.USD","LU0516422952.EUR","LU0359201612.USD","LU0327786744.USD","KURE","01276","LU0307460666.USD","LU1146622755.USD","BK0188","LU0405327148.USD","LU0561508036.HKD","LU0588546209.SGD","LU1580142542.USD","LU2039709279.SGD","02269","LU0128526141.USD","LU1997244956.HKD","IBBQ","LU0348827113.USD","BK1574","LU0043850808.USD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119210673","title":"再鼎医药(09688)依据2024年股权激励计划授出15,600份受限制美国存托股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1119210673","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119210673?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:17","pubTimestamp":1789121833,"startTime":"0","endTime":"0","summary":"2026年9月11日，再鼎医药有限公司公告披露，公司董事会已于2026年9月8日根据其2024年股权激励计划向6名员工参与者授出合共15,600份受限制股份单位，对应普通股156,000股。根据激励计划条款，该等RSU将在授出日起四年内按逐年各25%的比例归属，前提是获授人与集团的雇佣关系须持续至每个归属日。此次授出后，2024年股权激励计划下尚有61,600,963股普通股授权额度可供未来授出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666525377","title":"再鼎医药(09688)授出部分受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666525377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666525377?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:12","pubTimestamp":1789121556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年9月8日(美国东部时间)根据2024年股权激励计划授出部分受限制股份单位，涉及15.6万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4139","BK1574","09688","BK4526","LU2488822045.USD","BK4585","BK4548","BK4531","BK1161","BK1588","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666998175","title":"纳斯达克中国金龙指数跌超0.5%，再鼎医药跌5.03%，金山云跌4.26%，禾赛科技跌3.17%，晶科能源跌3.04%，","url":"https://stock-news.laohu8.com/highlight/detail?id=2666998175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666998175?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:30","pubTimestamp":1789047045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4124","LU2778985437.USD","HSAI","BK4139","LU2476274308.USD","BK4585","BK4519","HXC","ACES","BK4548","BK4588","KC","ZLAB","BK4526","JKS","LU2488822045.USD","BK4608","BK4141","BK4607","09688","BK4116","LU2476274720.SGD","03896","BK4531","BK4563","02525"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151193334","title":"异动解读｜再鼎医药盘中下跌5.1%，中报亏损扩大叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1151193334","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151193334?lang=zh_cn&edition=full","pubTime":"2026-09-10 14:00","pubTimestamp":1789020003,"startTime":"0","endTime":"0","summary":"9月10日，再鼎医药盘中下跌5.1%，报18.98港元，成交额9144.57万港元。消息面上，公司此前披露上半年业绩，总收入2.06亿美元，同比下降5%；净亏损1.02亿美元，同比扩大14%。研发开支增加14%至1.27亿美元，进一步拖累利润表现。此外，当日生物科技板块整体承压，云顶新耀跌8.2%、三生制药跌3.65%、信达生物跌3.26%，板块联动加剧个股调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再鼎医药走低，中报亏损扩大拖累股价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","06160","01093","LU0417516738.SGD","LU0181495838.USD","09926","KCE","06185","LU1226287792.SGD","LU1813983027.USD","LU0979878070.USD","LU2148510915.USD","LU1961090484.USD","06030","LU1969619763.USD","LU2580892862.HKD","LU0405327494.USD","LU1064130708.USD","LU0819121731.USD","LU1794554557.SGD","BK1161","LU1880383366.USD","09995","LU0463099449.HKD","LU1820825898.SGD","LU0348783233.USD","LU0348825331.USD","LU1655091616.SGD","02616","01877","IE0008369823.USD","09688","LU1255011170.USD","LU0516422952.EUR","LU1997245177.USD","BK1141","01801","KURE","IE00B543WZ88.USD","SG9999004220.SGD","LU0561508036.HKD","LU2039709279.SGD","LU1580142542.USD","BK0028","02269","02142","01177","LU0572944931.SGD","LU1226287875.USD","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","LU0828237510.HKD","LU0417516902.SGD","LU0348825331.USD","LU2476274308.USD","LU1720050803.USD","01789","BK1100","601066","HK0000165453.HKD","KCE","BK1141","IE00B5MMRT66.SGD","01530","09926","BK1585","LU1115378108.SGD","LU0228659784.USD","BK1207","02268","09688","KURE","LU2328871848.SGD","BK1191","LU2476274720.SGD","LU0348827113.USD","02367","06821","03933","LU2399975544.HKD","BK1161","LU0588546209.SGD","BK1588","LU0640798160.USD","SG9999004311.SGD","LU1969619763.USD","BK1574","02228","LU2488822045.USD","BK1515","LU1770034418.SGD","06160","01099","02196","BK1583","BK1197","BK1500","IE00B3M56506.USD","BK1593","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182558980","title":"再鼎医药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182558980","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182558980?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:46","pubTimestamp":1788515180,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司于2026年9月4日披露了截至2026年8月31日的证券变动月报表。在已发行股份及库存股方面，公司上月底及本月底的已发行普通股股数均为1,137,828,030股，库存股数为0股，表明2026年8月期间未发生新的股份发行、回购或注销，整体股本规模维持不变。公司在公告中亦确认截至2026年8月末已达到或符合适用的公众持股量要求。鉴于本期无新增股份发行与回购活动，公司股本结构保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664122038","title":"美股异动 | 再鼎医药涨逾7%，DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664122038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664122038?lang=zh_cn&edition=full","pubTime":"2026-09-02 21:58","pubTimestamp":1788357538,"startTime":"0","endTime":"0","summary":"消息面上，8月31日，$再鼎医药$在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。ZL-1310为一款靶向DLL3的ADC新药，采用宜联新一代ADC技术TMALIN构建，以TOPO1抑制剂作为payload，具有高效力、高清除率和高渗透性的作用特点。ZL-1310在小细胞肺癌PDX模型的临床前研究中显示出强效杀伤作用。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491227.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药DLL3 ADC启动一线SCLC全球三期临床","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","BK1588","BK4531","09688","BK4585","LU2488822045.USD","BK4588","BK1161","BK4526","ZLAB","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664898546","title":"再鼎医药早盘涨逾6% DLL3 ADC启动一线SCLC全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898546","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664898546?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:16","pubTimestamp":1788315360,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘涨逾6%。截至发稿，股价上涨5.97%，现报20.60港元，成交额5967.91万港元。8月31日，再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者，预计2030年6月初步完成。2026 年下半年重要催化剂包括：Zoci一线小细胞肺癌联合治疗数据公布、1L SCLC 及肺外神经内分泌癌注册性开发推进；ZL-1503首次人体数据公布等。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzme7832199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","BK4548","09688","BK1574","BK4139","BK1161","BK4531","ZLAB","BK4588","BK4585","BK4526","BK1588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":0.0424},{"period":"3month","weight":0.3769},{"period":"6month","weight":0.308},{"period":"1year","weight":-0.2264},{"period":"ytd","weight":0.5121}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052949},{"month":8,"riseRate":0.666667,"avgChangeRate":0.046005},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038078},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}